Redbiotec is a privately held Swiss Biopharmaceutical Company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the ETH Zurich, the company won several awards, including the renown W.A. De Vigier award. Redbiotec is backed by experienced institutional and private investors. Selected key investors are Zürcher Kantonalbank (ZKB Group), Switzerland’s largest cantonal bank, S&P AAA credit rating since 1994, and Redalpine Capital, a European seed and early-stage venture investor.